Toxic Epidermal Necrolysis
Last Posted: Nov 03, 2020
- Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome.
DeLozier Sarah et al. Journal of the American Medical Informatics Association : JAMIA 2020 Oct
- Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions.
Chang Chih-Jung et al. Frontiers in pharmacology 2020 11969
- Genetic Variants Associated with T-Cell Mediated Cutaneous Adverse Drug Reactions: A Prisma-Compliant Systematic Review - an EAACI Position Paper.
Oussalah Abderrahim et al. Allergy 2020 Jan
- Association of carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients
F Capule et al, PGX journal. January 3, 2020
- Genetic Predisposition to Anticonvulsant Hypersensitivity
M Pirmohamed, CPT, September 2019
- Genetic testing for prevention of severe drug-induced skin rash.
Alfirevic Ana et al. The Cochrane database of systematic reviews 2019 Jul 7CD010891
- Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States.
Choi Hyunmi et al. Epilepsia 2019 Jun
- Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions.
Pan R-Y et al. Clinical pharmacology and therapeutics 2017 102(1) 86-97
- Stevens-Johnson syndrome/toxic epidermal necrolysis in Jewish and Arab populations.
Firer Maria et al. Epilepsia 2018 59(7) 1469-1470
- Incidental Pharmacogenetics Findings in an HLA-related Research: Considerations for Primary Prevention.
Bakhtiar Faizal et al. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2019 Jan
- CLINGEN Actionability Report for Familial Mediterranean Fever (AD) - MEFV
ClinGen Actionability Working Group
- CLINGEN Actionability Report for Familial Mediterranean Fever (AR) - MEFV
ClinGen Actionability Working Group
- Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
Yu Kuang-Hui et al. International journal of rheumatic diseases 2017 Sep 20(9) 1057-1071
- Pharmacogenomics- Choosing the right medication at the right dose for each patient
NHGRI, Apr 2018
- Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population.
Mushiroda Taisei et al. JAMA neurology 2018 Apr
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.